OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 25,000 Shares of Inozyme Pharma, Inc. (NASDAQ:INZY)

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC cut its position in Inozyme Pharma, Inc. (NASDAQ:INZY) by 11.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 201,232 shares of the company’s stock after selling 25,000 shares during the period. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.31% of Inozyme Pharma worth $557,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Harvest Investment Services LLC acquired a new stake in Inozyme Pharma in the fourth quarter valued at approximately $31,000. Graham Capital Management L.P. acquired a new stake in Inozyme Pharma in the 4th quarter valued at $33,000. China Universal Asset Management Co. Ltd. acquired a new stake in Inozyme Pharma in the 4th quarter valued at $38,000. D. E. Shaw & Co. Inc. bought a new stake in Inozyme Pharma during the 4th quarter valued at $49,000. Finally, Palumbo Wealth Management LLC raised its holdings in Inozyme Pharma by 52.3% during the fourth quarter. Palumbo Wealth Management LLC now owns 23,281 shares of the company’s stock worth $64,000 after buying an additional 7,995 shares during the last quarter. 88.30% of the stock is owned by institutional investors.

Inozyme Pharma Price Performance

Inozyme Pharma stock opened at $1.09 on Wednesday. The company’s 50 day moving average price is $1.03 and its two-hundred day moving average price is $1.93. The company has a quick ratio of 7.68, a current ratio of 7.68 and a debt-to-equity ratio of 0.51. The stock has a market cap of $70.37 million, a P/E ratio of -0.70 and a beta of 1.35. Inozyme Pharma, Inc. has a 52 week low of $0.72 and a 52 week high of $6.24.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on INZY shares. Piper Sandler reduced their price objective on shares of Inozyme Pharma from $30.00 to $23.00 and set an “overweight” rating for the company in a report on Tuesday, March 11th. HC Wainwright reaffirmed a “buy” rating and issued a $16.00 price target on shares of Inozyme Pharma in a research report on Thursday, April 10th. Wedbush reissued an “outperform” rating and set a $7.00 price objective (down from $12.00) on shares of Inozyme Pharma in a report on Monday, March 10th. Raymond James lowered their price objective on Inozyme Pharma from $24.00 to $12.00 and set an “outperform” rating for the company in a research note on Wednesday, March 12th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $15.00 target price on shares of Inozyme Pharma in a research report on Tuesday, April 8th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Inozyme Pharma currently has a consensus rating of “Buy” and an average target price of $14.63.

Inozyme Pharma Profile

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.